Journal of Vascular Surgery
Volume 52, Issue 6 , Pages 1608-1615 , December 2010

Endothelial cells are susceptible to rapid siRNA transfection and gene silencing ex vivo

  • Nicholas D. Andersen, MD

      Affiliations

    • Department of Vascular Surgery Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Atish Chopra

      Affiliations

    • Department of Vascular Surgery Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Thomas S. Monahan, MD

      Affiliations

    • Department of Vascular Surgery Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Junaid Y. Malek, MD

      Affiliations

    • Department of Vascular Surgery Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Monica Jain, BS

      Affiliations

    • Boston University School of Medicine, Boston, Mass
    • ,
  • Leena Pradhan, PhD

      Affiliations

    • Department of Vascular Surgery Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Christiane Ferran, MD, PhD

      Affiliations

    • Department of Vascular Surgery Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • ,
  • Frank W. LoGerfo, MD

      Affiliations

    • Department of Vascular Surgery Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationReprint requests: Frank W. LoGerfo, MD, Beth Israel Deaconess Medical Center, LMOB, Ste. 3B, 110 Francis St., Boston, MA 02115

Received 3 April 2010 ,Accepted 27 June 2010.

References 

  1. Andersen ND, Monahan TS, Malek JY, Jain M, Daniel S, Caron LD, et al. Comparison of gene silencing in human vascular cells using small interfering RNAs. J Am Coll Surg. 2007;204:399–408
  2. Monahan TS, Andersen ND, Martin MC, Malek JY, Shrikhande GV, Pradhan L, et al. MARCKS silencing differentially affects human vascular smooth muscle and endothelial cell phenotypes to inhibit neointimal hyperplasia in saphenous vein. FASEB J. 2009;23:557–564
  3. Conte MS, Mann MJ, Simosa HF, Rhynhart KK, Mulligan RC. Genetic interventions for vein bypass graft disease: a review. J Vasc Surg. 2002;36:1040–1052
  4. Esper RJ, Nordaby RA, Vilarino JO, Paragano A, Cacharron JL, Machado RA. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol. 2006;5:4
  5. Rubanyi GM. The role of endothelium in cardiovascular homeostasis and diseases. J Cardiovasc Pharmacol. 1993;22(Suppl 4):S1–S14
  6. Friedewald VE, Giles TD, Pool JL, Yancy CW, Roberts WC. The Editor's Roundtable: endothelial dysfunction in cardiovascular disease. Am J Cardiol. 2008;102:418–423
  7. Mann MJ, Gibbons GH, Hutchinson H, Poston RS, Hoyt EG, Robbins RC, et al. Pressure-mediated oligonucleotide transfection of rat and human cardiovascular tissues. Proc Natl Acad Sci U S A. 1999;96:6411–6416
  8. Ramos JR, Berger K, Mansfield PB, Sauvage LR. Histologic fate and endothelial changes of distended and nondistended vein grafts. Ann Surg. 1976;183:205–228
  9. Boerboom LE, Olinger GN, Bonchek LI, Gunay II, Kissebah AH, Rodriguez ER, et al. The relative influence of arterial pressure versus intraoperative distention on lipid accumulation in primate vein bypass grafts. J Thorac Cardiovasc Surg. 1985;90:756–764
  10. LoGerfo FW, Quist WC, Crawshaw HM, Haudenschild C. An improved technique for preservation of endothelial morphology in vein grafts. Surgery. 1981;90:1015–1024
  11. Chatterjee A, Black SM, Catravas JD. Endothelial nitric oxide (NO) and its pathophysiologic regulation. Vascul Pharmacol. 2008;49:134–140
  12. Soyombo AA, Angelini GD, Bryan AJ, Jasani B, Newby AC. Intimal proliferation in an organ culture of human saphenous vein. Am J Pathol. 1990;137:1401–1410
  13. Soyombo AA, Angelini GD, Bryan AJ, Newby AC. Surgical preparation induces injury and promotes smooth muscle cell proliferation in a culture of human saphenous vein. Cardiovasc Res. 1993;27:1961–1967
  14. Kirkeby S, Thomsen CE. Quantitative immunohistochemistry of fluorescence labelled probes using low-cost software. J Immunol Methods. 2005;301:102–113
  15. Matkowskyj KA, Schonfeld D, Benya RV. Quantitative immunohistochemistry by measuring cumulative signal strength using commercially available software photoshop and matlab. J Histochem Cytochem. 2000;48:303–312
  16. Hollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC. Stem cell factor and c-kit are expressed by and may affect vascular SMCs through an autocrine pathway. J Surg Res. 2004;120:288–294
  17. Russ JC. The image processing handbook. 2nd ed.. Boca Raton: CRC Press; 1995;
  18. de Fougerolles A, Manoharan M, Meyers R, Vornlocher HP. RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics. Methods Enzymol. 2005;392:278–296
  19. Aigner A. Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol. 2006;2006:71659
  20. Miyagishi M, Hayashi M, Taira K. Comparison of the suppressive effects of antisense oligonucleotides and siRNAs directed against the same targets in mammalian cells. Antisense Nucleic Acid Drug Dev. 2003;13:1–7
  21. Sundaram P, Echalier B, Han W, Hull D, Timmons L. ATP-binding cassette transporters are required for efficient RNA interference in Caenorhabditis elegans. Mol Biol Cell. 2006;17:3678–3688
  22. Mannion JD, Ormont ML, Shi Y, O'Brien JE, Chung W, Roque F, et al. Saphenous vein graft protection: effects of c-myc antisense. J Thorac Cardiovasc Surg. 1998;115:152–161
  23. Kodama T, Tan PH, Offiah I, Partridge T, Cook T, George AJ, et al. Delivery of oligodeoxynucleotides into human saphenous veins and the adjunct effect of ultrasound and microbubbles. Ultrasound Med Biol. 2005;31:1683–1691
  24. Conte MS, Bandyk DF, Clowes AW, Moneta GL, Seely L, Lorenz TJ, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg. 2006;43:742–751discussion 751
  25. Alexander JH, Hafley G, Harrington RA, Peterson ED, Ferguson TB, Lorenz TJ, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA. 2005;294:2446–2454
  26. LoGerfo FW, Haudenschild CC, Quist WC. A clinical technique for prevention of spasm and preservation of endothelium in saphenous vein grafts. Arch Surg. 1984;119:1212–1214
  27. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet. 1999;354:1493–1498
  28. Desai ND, Fremes SE. Efficacy and safety of edifoligide. JAMA. 2006;295:1514;author reply 1514-5
  29. Dorn G, Patel S, Wotherspoon G, Hemmings-Mieszczak M, Barclay J, Natt FJ, et al. siRNA relieves chronic neuropathic pain. Nucleic Acids Res. 2004;32:e49

 Supported by National Institutes of Health R01 Grants HL021796, HL086741 (to CF and FL), and HL080130 (to CF), National Institutes of Health T32 Harvard-Longwood Research Training in Vascular Surgery Grant HL007734 (to TM and JM), a Howard Hughes Medical Institute Research Training Fellowship for Medical Students (to NA), The von Liebig Foundation (to ID, FE, MJ, LP, and FL), and the Royal College of Surgeons in Ireland Annual Appeal Alumni Research Fund (to AC).

 Competition of interest: none.

 The editors and reviewers of this article have no relevant financial relationships to disclose per the JVS policy that requires reviewers to decline review of any manuscript for which they may have a competition of interest.

PII: S0741-5214(10)01674-5

doi: 10.1016/j.jvs.2010.06.169

Journal of Vascular Surgery
Volume 52, Issue 6 , Pages 1608-1615 , December 2010

Article Tools

* Image Usage & Resolution